Cerenome Completes Enrollment in Phase 2 ReSPECT-GBM Trial
Cerenome completed enrollment in the Phase 2 ReSPECT-GBM trial of REYOBIQ in recurrent glioblastoma.
Related stories
Copt Defense Properties Reports Quarterly Results
Copt Defense Properties reported results for the quarter ended September 30.
M impact | EQUITY | Oct 29, 2026, 11:32 PM UTC
AIG Group 3Q New Business Margin Rises to 63.5%
The margin was up 5.3 percentage points year on year.
M impact | EQUITY | Oct 29, 2026, 11:30 PM UTC
Centerra Gold Reports Quarterly Results for Quarter Ended September 30
Centerra Gold reported results for the quarter ended September 30; no financial figures are provided.
M impact | EQUITY | Oct 29, 2026, 11:29 PM UTC
O'Reilly Automotive Announces Third-Quarter 2026 Results Release Availability
M impact | EQUITY | Oct 29, 2026, 11:29 PM UTC
O'Reilly Automotive Announces Q3 2026 Results Release Availability
O'Reilly Automotive announced the availability of its third-quarter 2026 results release.
M impact | EQUITY | Oct 29, 2026, 11:29 PM UTC
O'Reilly Automotive Announces Third-Quarter Results Release Availability
O'Reilly Automotive announced the availability of its third-quarter 2026 results release.
M impact | EQUITY | Oct 29, 2026, 11:29 PM UTC